Archives
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
KPT-330: Interpreting XPO1 Inhibition
2026-10-05
KPT-330, also known as Selinexor, is examined through an evidence-first lens that connects CRM1 biology with subtype-specific DLBCL findings. This analysis clarifies what the 2026 platinum-sensitization study demonstrates, what remains uncertain, and how the evidence informs cancer research.
-
FAK Inhibitor 14 in Ovarian Cancer Research
2026-10-05
A source-grounded overview of FAK signaling in cholesterol-adapted ovarian cancer models, with emphasis on the PARP1–FAK/Src–COL5A1 axis, the evidentiary role of FAK Inhibitor 14, and the limits of translating preclinical findings into therapeutic conclusions.
-
GI 254023X: Interpreting ADAM10 Evidence
2026-10-04
GI 254023X is a selective ADAM10 inhibitor for studying sheddase biology, Notch1 signaling, and endothelial barrier protection. This article presents an evidence-centered framework that connects its reported findings with lessons from BACE inhibition research without overstating translational relevance.
-
Anlotinib Hydrochloride: Evidence Beyond VEGFR2
2026-10-03
Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor whose anti-angiogenic profile is best understood through converging biochemical, endothelial, ex vivo, and in vivo evidence. This article examines what the data establish, where interpretation remains limited, and how the compound can inform cancer research without overstating translational conclusions.
-
ARCA Cy5 EGFP mRNA (5-moUTP) Workflow Guide
2026-10-02
ARCA Cy5 EGFP mRNA (5-moUTP) separates delivery from translation with a covalent Cy5 tracking signal and EGFP output. Use it to compare carriers, optimize mRNA transfection in mammalian cells, and troubleshoot uptake, localization, endosomal escape, and expression in one workflow.
-
Hyaluronic Acid Sodium Salt for ECM and siRNA Studies
2026-10-01
Hyaluronic acid sodium salt connects extracellular matrix modeling with high-molecular-weight biomaterial and siRNA nanoparticle workflows. This guide translates a preclinical Pseudomonas aeruginosa lung-injury study into practical formulation, assay, and troubleshooting decisions while emphasizing solubility and batch-validation controls.
-
Dantrolene Sodium Salt: Calcium Research Workflows
2026-10-01
Dantrolene sodium salt provides a mechanism-focused way to probe ryanodine receptor activity, intracellular calcium release, and calmodulin-dependent signaling. This practical guide connects calcium imaging, pancreatitis and neurodegeneration models, and carefully controlled exploratory CRISPR assays without overstating evidence across domains.
-
Trelagliptin succinate: Assay Workflow Guide
2026-09-30
This scenario-driven guide explains how Trelagliptin succinate (SKU A3889) can support reproducible cell viability, proliferation, cytotoxicity, and metabolic studies. It combines formulation guidance, model-specific concentration ranges, and analytical quality-control considerations with links to primary evidence.
-
Anlotinib hydrochloride Assay Workflows
2026-09-30
Build integrated angiogenesis experiments around Anlotinib hydrochloride, combining endothelial migration, capillary tube formation, viability, and receptor-phosphorylation readouts. The workflow distinguishes direct pathway inhibition from nonspecific toxicity while translating a clinically relevant case report into practical cancer research assay choices.
-
Mitoxantrone: A Transporter-Aware Framework
2026-09-29
Mitoxantrone research is more informative when cytotoxicity is interpreted alongside intracellular exposure and ABCG2-mediated efflux. This article develops a mechanistic framework for oncology and antiviral assays while connecting product handling to the 2024 marein–ABCG2 study.
-
Anlotinib Inhibits Angiogenesis via Three Kinases
2026-09-29
The reference study shows that anlotinib suppresses angiogenesis by jointly inhibiting VEGFR2, PDGFRβ, and FGFR1, with downstream attenuation of ERK signaling. Its combination of endothelial migration, tube formation, ex vivo vessel sprouting, and CAM assays provides a useful mechanistic framework for evaluating multi-target anti-angiogenic compounds.
-
Dual SMAD/Wnt Inhibition for iPSC-RGC Differentiation
2026-09-28
Chavali and colleagues developed a chemically defined differentiation strategy that combines dual SMAD and canonical Wnt inhibition to generate retinal ganglion cells (RGCs) from induced pluripotent stem cells (iPSCs) with improved yield and reproducibility. The approach produced RGC-enriched populations without genetic modification and incorporated Thy-1-based magnetic purification, providing a practical platform for glaucoma modeling and regenerative-ophthalmology research.
-
Temafloxacin Pharmacokinetics: Evidence and Implications
2026-09-28
This 1991 review integrates oral and intravenous temafloxacin data to explain its high bioavailability, prolonged elimination half-life, tissue distribution, and predominantly renal excretion. Its main contribution is a practical pharmacokinetic framework for interpreting dosing intervals and renal-function effects, while its findings remain specific to temafloxacin and the clinical evidence available at the time.
-
Citron OGD2 Links Iron Uptake to Canker Resistance
2026-09-27
The study identifies CmOGD2 as a contributor to citron resistance against citrus canker, linking iron acquisition and reactive oxygen species to a likely ferroptosis-related defense response. It also describes a regulatory circuit in which CmENO2 limits CmOGD2 expression through CmZAT10.1, while the Xanthomonas effector pthA4 appears to disrupt that restraint.
-
Thiazovivin (A5506) for Stem Cell Workflows
2026-09-26
Thiazovivin is a ROCK inhibitor used to support fibroblast reprogramming and human embryonic stem cell survival after trypsinization. This guide covers preparation and workflow controls; the dossier does not provide a cell-treatment dose, and the compound is for research use only—not diagnostic, clinical, or therapeutic use.